Sorted By:


PhRMA Comments to the 2017 National Trade Estimate Report

PhRMA  |  Policy Paper

The attached submission, presented to the Trade Policy Staff Committee of the Executive Office of the President on behalf of PhRMA and its member companies, identifies significant barriers to the export of goods, services and overseas direct investment for for inclusion in the 2017 National Trade Estimate Report (NTE).

ICYMI: Why 2017 medicine approvals matter

PhRMA  |  Blog Post

To learn more about the state of the biopharmaceutical pipeline, click here.

PhRMA and The ALS Association Report More Than 560 Medicines in Development for Rare Diseases

PhRMA  |  Press Release

View the full report here:   About PhRMAThe Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives.

PhRMA Statement on Institute of Medicine Report

PhRMA  |  Press Release

While PhRMA continues to review the IOM report in its entirety, we believe any conflict of interest policy should start with the premise that academia, physicians and companies share a responsibility to maintain ethical, professional relationships and exchange information for the benefit of patients.

2017 Direct to Consumer Advertising Survey Results

PhRMA  |  Report

This report covers the results of a survey conducted in April 2017 by Princeton Survey Research Associates International to learn about consumers' awareness of and opinions about direct to consumer advertisements of prescription medicines.

Point of Sale Rebate Analysis in the Commercial Market

PhRMA  |  Report

This report by Milliman observes the reallocation in payer costs and member cost sharing relative to a baseline scenario across varying plan designs typically found in the employer market.

PhRMA Statement Regarding AARP Rx Price Watch Report

PhRMA  |  Press Release

The report overemphasizes the impact of specialty medicines, which are used by a small number of beneficiaries and account for a small share of Medicare spending.

RA Report: Recognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis

PhRMA  |  Report

In recent years, we have seen significant progress in our ability to diagnose and manage chronic diseases. Among autoimmune conditions such as rheumatoid arthritis (RA), lupus, and multiple sclerosis, treatment advances have played a major role in slowing disease progression, improving quality of...

New Report: Decades of Drug Research Failures and Successes Transform Hepatitis C from Incurable to Curable Disease

PhRMA  |  Press Release

View the full “Twenty-Five Years of Progress Against Hepatitis C: Setbacks and Stepping Stones” report.

Let's Talk About Cost

PhRMA  |  From PhRMA

View reports that explore the slowdown in medicine cost growth, the rising cost of chronic disease, insurance coverage of medicine, the role of middlemen, and what our industry can do to make medicine more affordable for patients.

PhRMA Statement on the United Nations High Level Panel Report on Access to Medicines

PhRMA  |  Press Release

As such, neither this report nor its recommendations can be a sound basis for further consideration or action by the UN system.”

New Report: Transforming Rare Disease Patients' Lives Through Innovation

PhRMA  |  Press Release

For more information on rare diseases, view the “Medicines in Development for Rare Diseases” report.

Stakeholders raise concerns about ICER’s evidence report for non-small cell lung cancer

PhRMA  |  Blog Post

A key example would be the non-use of figure legends to explain the derivation of the figures throughout the report.

New report highlights more than 250 vaccines in development

PhRMA  |  Blog Post

View the full report here.

New report confirms competitive market works; Net prices for medicines increased just 2.8 percent in 2015

PhRMA  |  Blog Post

The report also found patients faced higher average cost exposure for branded medicines as coinsurance and pharmacy deductibles evolve.

PhRMA Statement on Annual Health Care Spending Report

PhRMA  |  Press Release

(January 5, 2009) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson issued the following statement today regarding the federal government’s annual health care spending report: "The annual report on healthcare spending released by the Centers for Medicare and Medicaid Services (CMS) shows that growth on spending for prescription medicines in 2007 was at an historic low of 4.9 percent.

Biopharmaceutical Research & Development: The Process Behind New Medicines

PhRMA  |  Report

Biopharmaceutical research companies invest considerable resources to move an investigational medicine through the complex and lengthy research and development process.

21st Century Cures: An Update on the President’s PCAST Report

PhRMA  |  Speeches & Communication

The Pharmaceutical Research and Manufacturers of America (PhRMA) believes that the challenges affecting the ability to provide life-saving and life-enhancing new medicines to patients in an efficient and timely manner are significant, and addressing them will require the involvement of and partne...

Medicines in Development for Rare Diseases 2016 Report

PhRMA  |  Report

Rare diseases, when taken together, are not that rare at all. In fact, 30 million Americans, or 10 percent of the population, have one of the 7,000 known rare diseases, of which 80 percent are genetic in origin. Half of those affected worldwide are children. A disease is generally defined as “rar...

Berkeley Research Group Study on the Pharmaceutical Supply Chain

PhRMA  |  Report

For purposes of this paper, we begin the analysis with “initial gross drug expenditures,” which we define as the sum of payments for prescription drugs made by patients and their health plans at the point of sale (e.g., pharmacy, outpatient hospital) prior toany rebate, discount, or fee provided ...

An Analysis of Exchange Plan Benefits for Certain Medicines

Access Better Coverage  |  From Our Network

Additional oversight and stronger standards for formulary design would help prevent the practices described in this report.

Biopharmaceutical Company Communications with Health Care Stakeholders

PhRMA  |  Report

Download the report to learn more.

PhRMA and Epilepsy Foundation Report More Than 400 Medicines in Development to Treat Neurological Disorders

PhRMA  |  Press Release

The new report, “Medicines in Development for Neurological Disorders,” demonstrates how the newest advancements seek to treat the underlying mechanisms of neurological disorders.

PhRMA Statement on the ITC Report on India

PhRMA  |  Press Release

International Trade Commission’s second report in September 2015.

EFPIA-PhRMA Principles for Responsible Clinical Trial Data Sharing

PhRMA  |  Report

The EFPIA-PhRMA Principles build on existing industry commitments to trial registration and routine disclosure of summary results (which are both now legislative and/or regulatory requirements in the major global markets), in addition to publication in scientific literature....

You have reviewed the first 150 results out of 1012. Each page contains 25 results. You're on page 6.

prev 1 2 3 4 5 6 next